MG
PHAT icon

Michael Gelband’s Phathom Pharmaceuticals PHAT Stock Holding History

Michael Gelband’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13,293
Closed -$148K – 1950
2026
Q1 		$148K Sell
13,293
-9,108
-41% -$115K ﹤0.01% 1411
2025
Q4 		$372K Sell
22,401
-48,874
-69% -$698K ﹤0.01% 1253
2025
Q3 		$839K Buy
71,275
+56,129
+371% +$579K 0.01% 1024
2025
Q2 		$145K Sell
15,146
-64,165
-81% -$355K ﹤0.01% 1341
2025
Q1 		$497K Buy
+79,311
New +$482K ﹤0.01% 1114
2024
Q4 		– Sell
-69,282
Closed -$1.25M – 1931
2024
Q3 		$1.25M Buy
+69,282
New +$968K 0.01% 907
2023
Q4 		– Sell
-17,008
Closed -$176K – 1920
2023
Q3 		$176K Buy
+17,008
New +$233K ﹤0.01% 1541
2021
Q2 		– Sell
-7,534
Closed -$283K – 2695
2021
Q1 		$283K Buy
+7,534
New +$315K ﹤0.01% 1716
2020
Q2 		– Sell
-18,765
Closed -$485K – 1965
2020
Q1 		$485K Buy
+18,765
New +$627K 0.03% 501

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Michael Gelband's PHAT Position: Q2 2026 in Review

Michael Gelband sold out of Phathom Pharmaceuticals (PHAT) in Q2 2026, closing a stake of 13,293 shares — an estimated $148K sold.

Michael Gelband first reported a position in PHAT in Q1 2020 and held it in 9 quarters. The position peaked at $1.25M in Q3 2024. 161 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • Michael Gelband reported no remaining Phathom Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Michael Gelband sold 13,293 Phathom Pharmaceuticals shares in Q2 2026, an estimated $148K.
  • Michael Gelband first reported a position in Phathom Pharmaceuticals in Q1 2020 and held it in 9 quarters.
  • Michael Gelband's Phathom Pharmaceuticals position peaked at $1.25M in Q3 2024.
  • 161 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.